Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2967265 | Journal of Clinical Lipidology | 2007 | 8 Pages |
Abstract
These data indicate that, in coronary artery disease patients with low HDL, treating the atherogenic dyslipidemia with a combination of N+S leads to substantial benefits in terms of stenosis progression and clinical events, independently of whether the patient has the metabolic syndrome or is insulin-resistant. During a 3-year period, the beneficial effect of niacin in combination with simvastatin appears to offset the modest adverse effect of niacin on glucose metabolism and insulin resistance in at higher-risk patients, as long as careful attention is paid to glycemic control.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Francesca MD, PhD, Alan MD, Josh S. BS, Brian BA, B. Greg MD, PhD, Xue-Qiao MD,